Etani Yuki

エタニユウキ | Etani Yuki

Affiliation and department：

Research field (3)： Medical biochemistry , Orthopedics , Orthopedics

Research keywords (4)：骨代謝 , 骨粗鬆症 , 足の外科 , 関節リウマチ

Research theme for competitive and other funds (3)：

2023 - 2025 新規Nuclear factor kappa B(NF-κB)阻害ペプチドによる新規骨粗鬆症治療法の開発
2023 - 2024 Impact of Seropositivity on the Therapeutic Outcomes of Biologic DMARDs and JAK Inhibitors: Analysis from the ANSWER Cohort
2021 - 2023 新規NF-κB阻害ペプチドによる新規変形性関節症治療法の開発

Papers (47)：

Takaaki Noguchi, Makoto Hirao, Kosuke Ebina, Yuki Etani, Gensuke Okamura, Manabu Sakata, Taihei Miura, Seiji Okada, Jun Hashimoto. Mid-term outcomes of distal tibial oblique osteotomy in patients with rheumatoid arthritis: a report of three cases. Modern rheumatology case reports. 2024
Gensuke Okamura, Makoto Hirao, Takaaki Noguchi, Yuki Etani, Kosuke Ebina, Taihei Miura, Hideki Tsuboi, Atsushi Goshima, Seiji Okada, Jun Hashimoto. Arthroscopic treatment of septic arthritis of the ankle joint caused by streptococcus in patients with chronic inflammatory diseases: two case reports. Modern rheumatology case reports. 2024
Kosuke Ebina, Yuki Etani, Takaaki Noguchi, Ken Nakata, Seiji Okada. Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis. Journal of bone and mineral metabolism. 2024
Gensuke Okamura, Makoto Hirao, Takaaki Noguchi, Yuki Etani, Kosuke Ebina, Takuya Kurihara, Atsushi Goshima, Hideki Tsuboi, Shigeyoshi Tsuji, Kenji Takami, et al. Flatfoot Surgery for Flexible Progressive Collapsing Foot Deformity With Inflammatory Joint Diseases: A Report of 3 Cases. JBJS case connector. 2024. 14. 3
Shohei Oyama, Takashi Kanamoto, Kosuke Ebina, Yuki Etani, Makoto Hirao, Atsushi Goshima, Shunya Otani, Minami Hikida, Satoshi Yamakawa, Shohei Ito, et al. Cyclic compressive loading induces a mature meniscal cell phenotype in mesenchymal stem cells with an atelocollagen-based scaffold. Frontiers in Bioengineering and Biotechnology. 2024. 12

ｍore...

MISC (103)：

蛯名耕介, 惠谷悠紀, 岡田誠司, 中田研. 骨形成促進作用を有する薬剤の効果と役割逐次療法. 日本骨粗鬆症学会雑誌. 2023. 9. Suppl.1. 182-182
蛯名耕介, 惠谷悠紀, 中田研, 岡田誠司. 骨粗鬆症治療の最適化骨形成促進剤の果たすべき役割. 日本骨粗鬆症学会雑誌. 2023. 9. Suppl.1. 298-298
蛯名耕介, 惠谷悠紀, 野口貴明, 中田研, 岡田誠司. 関節炎の診療・研究の最前線関節リウマチに伴う関節破壊機序とその対策. 日本整形外科学会雑誌. 2023. 97. 8. S1580-S1580
平尾眞, 野口貴明, 岡村元佑, 惠谷悠紀, 蛯名耕介, 坪井秀規, 橋本淳. 変形性足関節症の診療・研究の最前線変形性足関節症に対する人工足関節置換術(FINE ankle system). 日本整形外科学会雑誌. 2023. 97. 8. S1593-S1593
蛯名耕介, 惠谷悠紀, 岡田誠司, 中田研. 骨粗鬆症治療の最適化骨形成促進剤の果たすべき役割. 日本整形外科学会雑誌. 2023. 97. 8. S1556-S1556

ｍore...

Books (2)：

Work history (11)：

2024/09 - 現在 Osaka University Department of Sports Medical Biomechanics, Graduate School of Medicine
2024/04 - 現在 Graduate School of Medicine, Osaka University Department of Sports Medical Biomechanics
2023/07 - 2024/03 Osaka University Department of Musculoskeletal Regenerative Medicine, Graduate School of Medicine
2020/10 - 2023/06 大阪大学大学院医学系研究科整形外科医員
2017/04 - 2021/03 大阪大学大学院医学系研究科博士課程修了

Show all

Committee career (2)：

2024/04 - 現在 Japan College of Rheumatology councilor
2023/09 - 現在 Japanese Society of Rheumatology Kinki Branch Academic Meeting program committee

Awards (6)：

2024/10 - Japan Osteoporosis Society Excellent presentation award Can Bone Turnover Markers at Treatment Initiation Serve as Indicators for Optimal Drug Selection? Differences in Bone Mineral Density Increases Among Romosozumab, Teriparatide, and Denosumab in Primary Osteoporosis Based on Bone Turnover Markers
2024/10 - Japan Osteoporosis Society Research Encouragement Award
2024/05 - Japan Orthopaedics and Traumatology Foundation Foundation Award Exploration of a Novel Osteoporosis Treatment Using Small Molecule Peptides with Anti-Nuclear Factor Kappa B (NF-κB) Activity
2024/04 - The 68th Annual Meeting of the Japan College of Rheumatology Outstanding Poster Award Study on Differences in Bio/JAK Inhibitor Treatment for RA Patients Between Immunology and Orthopedic Departments: ANSWER Cohort
2023/08 - 第32回日本リウマチ学会近畿支部学術集会優秀演題賞

Show all

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page